Randomized controlled trial of antenatal magnesium sulfate for short-term neuroprotection in premature neonates
DOI:
https://doi.org/10.32677/IJCH.2017.v04.i02.020Keywords:
Antenatal magnesium sulfate, Intraventricular hemorrhage, Neuroprotection, Preterm infantsAbstract
Objective: To test the hypothesis that antenatal magnesium sulfate (MgSO4) has a short term neuroprotective role in the early neonatal period, when given to women considered at risk for preterm delivery in a developing country. Study Design: Randomized, placebo-controlled, open label, trial. Participants: A total of 126 mothers who delivered at or below 34 weeks gestation were randomized to receive either antenatal MgSO4 (cases) or normal saline as placebo (controls). A total of 108 babies born were observed for the primary and secondary outcomes. Primary Outcome: The composite of the incidence of death and intraventricular hemorrhage (IVH) by cranial ultrasonography in surviving preterm infants. Results: There were 6 deaths in cases and 11 deaths in controls (relative risk [RR]: 0.54; 95% confidence interval [CI]: 0.2173-1.369; p=0.18). A statistically significant reduction in the number of IVH was observed in cases (n=1) compared to controls (n=9) (RR: 0.11; 95% CI: 0.0145-0.897; p=0.016) with a number needed to treat of 7. Conclusion: Antenatal MgSO4 resulted in a significant reduction in the risk of IVH in preterm infants born at or below 34 weeks of gestation.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 1970 Manoj Varanattu C, Bindu Menon, Ajay Sankar, Anand M, Prakash Manikoth
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.